Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2006-09-05
2006-09-05
Peselev, Elli (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S008100, C514S021800, C514S034000, C514S052000, C530S300000, C530S394000
Reexamination Certificate
active
07101842
ABSTRACT:
Targeting agents such as transferrin and transcobalamin can be conjugated with anti-protozoan drugs for the treatment of protozoan infections. Any suitable anti-protozoan drug can be used, preferably the drug is selected from the group consisting of apoptosis inducing compounds, cytotoxic antibiotics, alkalating agents, plant toxins, and bacterial mutant toxins. The targeting agent is preferably coupled to the antiprotozoan drug by means of glutaraldehyde.
REFERENCES:
patent: 4866780 (1989-09-01), Mertz et al.
patent: 4886780 (1989-12-01), Faulk
patent: 4895714 (1990-01-01), Faulk
patent: 5000935 (1991-03-01), Faulk
patent: 5268165 (1993-12-01), Hedlund et al.
patent: 6054133 (2000-04-01), Horwitz et al.
patent: 6183723 (2001-02-01), Seetharam et al.
Faulk WP and Johnson PM. Immunological studies of human placentae. Identification and distribution of proteins in mature chorionic villi. Clin Exp Immunol 1977; 27: 365-375.
Faulk WP, Johnson PM, Dorling J and Temple A. Non-specific factors of resistance in human placentae. prot Biol Fluids 1976; 24: 139-142.
Johnson PM and Faulk WP. Immunological studies of human placentae: Identification and distribution of proteins in immature chorionic villi. Immunology 1978; 34: 1027-1035.
Faulk WP and Galbraith GMP. Trophoblast transferrin and transferrin receptors in the host-parasite relationship of human pregnancy. Proc R Soc Lond B 1979; 204: 83-97.
Hsi, BL, Yeh CJG and Faulk WP. Human amniochorion: Tissue-specific markers, transferrin receptors and histocompatibility antigens. Placenta 1982; 3: 1-12.
Yeh CJG, Hsi BL and Faulk WP. Histocompatibility antigens, transferrin receptors and extra-embryonic markers of human amniotic epithelial cellsin vitro. Placenta 1983; 4: 361-368.
Galbraith GMP, Galbraith RM and Faulk WP. Transferrin binding by human lymphoblastoid cell lines and other transformed cells. Cell Immunology 1980; 49: 215-222.
Faulk WP, Hsi BL and Stevens PJ. Transferrin and transferrin receptors in carcinoma of the breast. Lancet 1980; ii: 390-392.
Yeh CJG, Taylor C and Faulk WP. Transferrin binding by peripheral blood mononuclear cells in human lymphomas, myelomas and leukemias. Vox Sanguinis 1984; 46: 217-223.
Faulk WP, Harats H and Berczi A. Transferrin receptor growth control in normal and abnormal cells. In:Oxidoreduction at the Plasma Membrane. vol. 1. (eds., FL Crane, JD Morre and H Low) CRC Press, Boca Raton, FL, 1990; pp. 205-224.
Yang DC, Wang F, Elliott RL and Head JF. Expression of transferrin receptor and ferritin H-chain mRNA are associated with clinical and histopathological prognostic indicators in breast cancer. Anticancer Res 2001; 21: 541-549.
Barnett D, Wilson GA, Lawrence AC and Buckley GA. Transferrin receptor expression in the leukaemias and lymphoproliferative disorders. Clin Lab Haematol 1987; 9: 361-70.
Whitney JF, Clark JM, Griffin TW, Gautam S and Leslie KO. Transferrin receptor expression in nonsmall cell lung cancer. Histopathologic and clinical correlates, Cancer 1995; 76: 20-25.
Recht L, Torres CO, Smith TW, Raso V and Griffin TW. Transferrin receptor in normal and neoplastic brain tissue: implications for brain-tumor immunotherapy. J Neurosurg 1990; 72: 941-945.
Sciot R, Paterson AC, van Eyken P, Callea F, Kew MC and Desmet VJ. Transferrin receptor expression in human hepatocellular carcinoma: an immunohistochemical study of 34 cases. Histopathol 1988; 12: 53-63.
Seymour GJ, Walsh MD, Lavin MF, Strutton G and Gardiner RA. Transferrin receptor expression by human bladder transitional cell carcinomas. Urol Res 1987; 15: 341-344.
Lindholm ML, Lindberg LA, Vilja P, Puolakka VM, Nordling S, Schroder T and Schroder J. Expression of the human transferrin receptor in subrenal capsule assay in the mouse. J Surg Oncol 1988; 38: 57-62.
Hereiz HA and Bayoumi FA. Evaluation of diagnosis of ovarian malignancy using immunohistochemical technique. J Egyptian Public Hlth Assoc 1992; 67: 697-707.
Medeiros LJ, Picker LJ, Horning SJ and Warnke RA. Transferrin receptor expression by non-Hodgkin's lymphomas. Correlation with morphologic grade and survival. Cancer 1988; 61: 1844-1851.
Soyer HP, Smolle J, Torne R and Kerl H. Transferrin receptor expression in normal skin and in various cutaneous tumors. J Cutaneous Pathol 1987; 14: 1-5.
Lesley J, Hyman R, Schulte R and Trotter J. Expression of transferrin receptor on murine hematopoietic progenitors. Cell Immunol 1984; 83: 14-25.
Testa U, Pelosi E and Peschle C. The transferrin receptor. Crit Rev Oncogen 1993; 4: 241-276.
Bothwell TA, Charlton RW, Cook JD and Finch CA.Iron Metabolism in Men, Blackwell Scientific, Oxford, 1979.
Ponka P and Lok CN. The transferrin receptor: role in health and disease. Int J Biochem Cell Biol 1999; 31: 1111-1137.
Hamilton TA, Gray PW and Adams DO. Expression of the transferrin receptor on murine peritoneal macrophages is modulated by in vitro treatment with interferon gamma. Cell Immunol 1984; 89: 478-488.
Byrd TF and Horowitz MA. Interferon gamma-activated human monocytes downregulate transferrin receptors and inhibits the intracellular multiplication ofLegionella. pneumophilaby limiting the availability of iron. J Clin Invest 1989; 83: 1457-1465.
Kronke M, Leonard W, Depper JM and Greene WC. Sequential expression of genes involved in human T lymphocyte growth and differentiation J Exp Med 1985; 161: 1593-1598.
Galbraith RM and Galbraith GM. Expression of transferrin receptors on mitogen-stimulated human peripheral blood lymphocytes: relation to cellular activation and related metabolic events. Immunology 1983; 133: 703-710.
Neckers LM and Cossman J. Transferrin receptor induction in mitogen-stimulated human T lymphocytes is required for DNA synthesis and cell division and is regulated by interleukin 2, Proc Nat Acad Sci USA 1983; 80: 3494-3498.
Testa U, Kuhn L. Petrini M, Quaranta MT, Pelosi E and Peschle C. Differential regulation of iron regulatory element-binding protein(s) in cell extracts of activated lymphocytes versus monocytes-macrophages. J Biol Chem 1991; 266: 3925-3930.
Seiser C, Texieira S and Kuhn LC. Interleukin-2-dependent transcriptional and post-transcriptional regulation of transferrin receptor mRNA. J Biol Chem 1993; 268: 13,074-13, 080.
Neckers, LM, Yenokida G and James SP. The role of the transferrin receptor in human B lymphocyte activation. J Immunol 1984; 133: 2437-2441.
Neckers LM and Trepel JB. Transferrin receptor expression and the control of cell growth. Cancer Invest 1986; 4: 461-470.
Yeh CJG, Papamichall M and Faulk WP. Loss of transferrin receptors following induced differentiation of HL-60 promyelocytio leukemia cells. Exper Cell Res 1982; 138: 429-431.
Barker KA and Newburger PE. Relationship between the cell cycle and the expression c-myc and transferrin receptor genes during induced myeloid differentiation. Exper Cell Res 1990; 186: 1-5.
Klausner RD, Rouault TA and Harford JB. Regulating the fate of mRNA: the control of cellular iron metabolism. Cell 1993; 72: 19-28.
Haile DJ. Regulation of genes of iron metabolism by the iron-response proteins. Am J Med Sciences 1999; 318: 230-240.
Gatter KC, Brown G, Trowbridge IS, Woolston RE and Mason DY. Transferrin receptors in human tissues: their distribution and possible clinical relevance. J Clin Pathol 1983; 36: 539-545.
Faulk WP and Hunt JS. Human placentae: view from an immunological bias. Am J Reprod Immunol 1990; 21: 108-113.
Broadwell RD, Baker-Caims BJ, Friden PM, Oliver C and Villegas JC. Transcytosis of protein through the mammalian cerebral epithelium and endothelium. III. Receptor mediated transcytosis through the blood-brain barrier of blood-borne transferrin and antibody against transferrin receptor. Exp Neurol 1996; 142: 47-65.
Ponka P, Beaumont C and Richardson DR. Function and regulation of transferrin and ferritin. Seminars in Hematol 1998; 35: 35-54.
Sylvester SR and Griswold MD. The testicular iron shuttle A “nurse” function of the Sartoli cells. J Androl 1994; 15: 381-385.
Yeh CJG and Faulk WP. Killing of human tumor cells in culture with adriamycin conjugates of human transferrin. Clin Immunol Immunopath. 1984; 32: 1-11.
Y
Faulk Pharmaceuticals, Inc.
Peselev Elli
Rothwell Figg Ernst & Manbeck P.C.
LandOfFree
Targeted delivery of drugs for the treatment of parasitic... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Targeted delivery of drugs for the treatment of parasitic..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Targeted delivery of drugs for the treatment of parasitic... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3535794